‾‾‾|‾‾‾-shaped Innovator | Health & Tech | 🏃🏻 Workshops, hackathons, rapid prototyping 🚀 powered by generative AI & automation
Antwerp
Joined June 2008
- Tweets53K
- Following1.4K
- Followers5.7K
- Likes17.7K
the answer lies in hospitals offering the scaffolding / environment for those tools to being developed in a safe way
Bart Collet retweeted
25,000 people are on the waitlist for a $499 scan at Neko Health's New York clinic. England's NHS waiting list is 7.33 million treatments, 111,000 of them over a year. One queue reads as demand, the other as failure; the difference is not the length but whether you chose to stand in it.
The same inversion runs through AI. Blue Cross Blue Shield links hospitals' AI coding to $942 million in extra costs from 2023 to 2025, about 70% of it from diagnoses that changed no care. Meanwhile retailers pull out self-checkouts and clinics install AI receptionists.
Does your next AI purchase give a patient more of a person, or a process?
hyperadvancer.com/blog/same-…
Before you buy a partner-scouting tool, try one test: describe your ideal partner in a single sentence.
If you can't, no amount of filtering will help. You are not at the search stage yet.
The teams that keep finding good partners don't pick one method and defend it. They stack three: widen the field with a generative or AI method, qualify the survivors in a curated database, then warm up the finalists through an event or a direct introduction. The first step is the one most teams skip.
Which step does your scouting process quietly leave out?
roulette.hyperadvancer.com/b…
Bart Collet retweeted
$45,000 a year is the top of the hospital longevity market. Northwestern, Weill Cornell and Mayo Clinic all sell cash-pay longevity care: Weill Cornell charges $12,000 a year, $7,500 for a baseline, MRI on top.
Weill Cornell's FAQ gives the motive away. The goal, it says, is to prove the clinical value of longevity care so insurers eventually reimburse it. That is a trial with the money running backwards: in a study the hospital pays the patient; here the patient pays the hospital.
A GLP-1 drug with the SELECT trial behind it cannot show an insurer savings. What is a whole-body MRI proving?
hyperadvancer.com/blog/payin…
4 minutes 25 seconds. That's how long a Paris intensivist took to build a bedside ventilator assistant for ARDS.
Sacha Rozencwajg (AP-HP Bichat) wrote an eight-block clinical spec for Claude Opus 4.6 and got a tool that computes tidal volume, driving pressure and mechanical power, with live alerts. 1,400 automated checks, zero formula errors.
The five minutes is the headline. The spec and the test suite are the real work, and both are clinical knowledge. If prompt engineering becomes a clinical skill, who checks the tools the next thousand physicians build?
sciencedirect.com/science/ar…
Bart Collet retweeted
Finally, you can get real healthcare directly from your Claude, ChatGPT, GrokBot, Muse, or Instinct.
Just tell them to use FutureClinic. Agents welcome.
Healthcare will never be the same again.
Backed by @ycombinator
What stood out: attackers are using both open and closed AI models, so locking down frontier labs does not close the door.
AI agents find software flaws far faster than people can. Discovery is now cheap; patching is still a human queue with meetings in it.
The likely result is a safer internet that is also less open: more identity checks, more gatekeeping, more walled gardens in the name of defence.
Did openness only work while attackers were slow?
50+ longevity events for 2027 are already on our calendar, and next year's conference budgets are being set right now.
The first call is Europe or the US. It looks like a geography question. It is really a question about what you want to walk out with.
The newest science, or a clear read on policy and regulation: Europe. Founders, investors, or the consumer wellness and biohacking scene: the US. And if you want the most events per trip, Europe wins on shorter, denser clusters.
What is the one thing your team needs from a longevity conference next year?
longevents.hyperadvancer.com…
Hey @Ryanair , how about soft seats for an extra 25 eur instead of the standard uncushioned ones? 💡
Bart Collet retweeted
There's a lot in a face photograph about health that AI can detect, as seen in this foundation model of >40 million face images, including outcomes from cancer, biological age, influence of lifestyle factors, and survival @LancetDigitalH
thelancet.com/journals/landi…
25,000 people are on the waitlist for a $499 scan at Neko Health's New York clinic. England's NHS waiting list is 7.33 million treatments, 111,000 of them over a year. One queue reads as demand, the other as failure; the difference is not the length but whether you chose to stand in it.
The same inversion runs through AI. Blue Cross Blue Shield links hospitals' AI coding to $942 million in extra costs from 2023 to 2025, about 70% of it from diagnoses that changed no care. Meanwhile retailers pull out self-checkouts and clinics install AI receptionists.
Does your next AI purchase give a patient more of a person, or a process?
hyperadvancer.com/blog/same-…
Bart Collet retweeted
In 2022 they stopped together after 101 yards.
In 2024 they stopped together (along with Frank Gielen) after 110 yards.
These guys are good friends. Of course they were going to stop together this time as well, after setting a new world best.
Bart Collet retweeted
Health Tech Sessions in Leuven: "Europa heeft innovatie, maar moet sneller schakelen" - numerikare.be/nl/nieuws/sant… @Leuven_MindGate @BEMEDTECHTWEET @bart
Bart Collet retweeted
Thank you so much, Bart! Really appreciate you including RemCard in Clinicians That Code and supporting clinicians who build their own tools. It’s great to see my project recognized by the community! I’ll definitely add the badge to the GitHub README and website.
$45,000 a year is the top of the hospital longevity market. Northwestern, Weill Cornell and Mayo Clinic all sell cash-pay longevity care: Weill Cornell charges $12,000 a year, $7,500 for a baseline, MRI on top.
Weill Cornell's FAQ gives the motive away. The goal, it says, is to prove the clinical value of longevity care so insurers eventually reimburse it. That is a trial with the money running backwards: in a study the hospital pays the patient; here the patient pays the hospital.
A GLP-1 drug with the SELECT trial behind it cannot show an insurer savings. What is a whole-body MRI proving?
hyperadvancer.com/blog/payin…
